146 related articles for article (PubMed ID: 37822311)
1. Prevalence and predictors of metabolic-associated fatty liver disease in liver transplant recipients: A cross-sectional prospective study.
Adali G; Bilgic NM; Kalaman AE; Ozturk O; Ozdil K
Hepatol Forum; 2023; 4(3):129-134. PubMed ID: 37822311
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of de novo metabolic dysfunction-associated fatty liver disease after liver transplantation and the role of controlled attenuation parameter.
Mak LY; Chan AC; Wong TC; Dai WC; She WH; Ma KW; Sin SL; Chu KW; Seto WK; Yuen MF; Lo CM; Fung J
BMC Gastroenterol; 2023 Sep; 23(1):307. PubMed ID: 37700227
[TBL] [Abstract][Full Text] [Related]
3. Liver disease prevalence and severity in people with serious mental illness: a cross-sectional analysis using non-invasive diagnostic tools.
Braude MR; Con D; Lubel J; Bidwai A; Nguyen HT; Sharmamiglani S; Clarke D; Dev A; Sievert W
Hepatol Int; 2021 Jun; 15(3):812-820. PubMed ID: 34081288
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and risk factors of metabolic associated fatty liver disease among people living with HIV in China.
Liu D; Shen Y; Zhang R; Xun J; Wang J; Liu L; Steinhart C; Chen J; Lu H
J Gastroenterol Hepatol; 2021 Jun; 36(6):1670-1678. PubMed ID: 33140878
[TBL] [Abstract][Full Text] [Related]
5. Ultrasound and FibroScan
Salmi A; di Filippo L; Ferrari C; Frara S; Giustina A
Endocrine; 2022 Nov; 78(2):262-269. PubMed ID: 35980569
[TBL] [Abstract][Full Text] [Related]
6. Identifying inflammatory bowel disease patients at risk of metabolic dysfunction-associated fatty liver disease: usefulness of non-invasive steatosis predictive scores.
Capela TL; Silva VM; Freitas M; Arieira C; Gonçalves TC; de Castro FD; Magalhães J; Cotter J
BMC Gastroenterol; 2023 Dec; 23(1):437. PubMed ID: 38093213
[TBL] [Abstract][Full Text] [Related]
7. Liver Steatosis: Better Predictor of CKD in MAFLD Than Liver Fibrosis as Determined by Transient Elastography With Controlled Attenuation Parameter.
Marc L; Mihaescu A; Lupusoru R; Grosu I; Gadalean F; Bob F; Chisavu L; Olariu N; Tucicovschi V; Timar B; Sporea I; Timar R; Schiller A
Front Med (Lausanne); 2021; 8():788881. PubMed ID: 35096879
[No Abstract] [Full Text] [Related]
8. Prevalence and predicting factors of metabolic-associated fatty liver disease diagnosed by transient elastography with controlled attenuation parameters in HIV-positive people.
Jongraksak T; Sobhonslidsuk A; Jatchavala J; Warodomwichit D; Kaewduang P; Sungkanuparph S
Int J STD AIDS; 2021 Mar; 32(3):266-275. PubMed ID: 33334267
[TBL] [Abstract][Full Text] [Related]
9. Prevalence of metabolic dysfunction-associated fatty liver disease in kidney transplant recipients: A cross-sectional study using FibroScan.
Yesil EE; Yilmaz Y; Yesil A; Mese M; Kaya E; Bakir EA
Hepatol Forum; 2023 Jan; 4(1):14-18. PubMed ID: 36843889
[TBL] [Abstract][Full Text] [Related]
10. Accuracy of FibroTouch in assessing liver steatosis and fibrosis in patients with metabolic-associated fatty liver disease combined with type 2 diabetes mellitus.
Yu H; Liu H; Zhang J; Jia G; Yang L; Zhang Q; Li G; Liu F; Di F; Wang F
Ann Palliat Med; 2021 Sep; 10(9):9702-9714. PubMed ID: 34628896
[TBL] [Abstract][Full Text] [Related]
11. Association of metabolic dysfunction-associated fatty liver disease with chronic kidney disease: a Chinese population-based study.
Hu Q; Chen Y; Bao T; Huang Y
Ren Fail; 2022 Dec; 44(1):1996-2005. PubMed ID: 36374233
[TBL] [Abstract][Full Text] [Related]
12. [Applied research of ultrasound attenuation parameter in the diagnosis of metabolic dysfunction-associated fatty liver disease].
Hou MM; Yuan XW; Wang YQ; Zhang Y; Zhang SY; Yu SH; Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2022 Mar; 30(3):290-296. PubMed ID: 35462485
[No Abstract] [Full Text] [Related]
13. Metabolic dysfunction-associated fatty liver disease in people living with HIV.
Michel M; Labenz C; Armandi A; Kaps L; Kremer WM; Galle PR; Grimm D; Sprinzl M; Schattenberg JM
Sci Rep; 2023 Jun; 13(1):9158. PubMed ID: 37280241
[TBL] [Abstract][Full Text] [Related]
14. Discrepancies between Nonalcoholic and Metabolic-associated Fatty Liver Disease by Multiple Steatosis Assessment.
Shao C; Ye J; Li X; Lin Y; Feng S; Liao B; Wang W; Gong X; Zhong B
J Clin Transl Hepatol; 2022 Dec; 10(6):1013-1026. PubMed ID: 36381107
[TBL] [Abstract][Full Text] [Related]
15. Associations of Serum Iron Status with MAFLD and Liver Fibrosis in the USA: a Nationwide Cross-Section Study.
Yu G; Liu L; Qin T; Luo Y; Song C; Chen X; Duan H; Jiang Y; Zeng H; Wan H; Shen J
Biol Trace Elem Res; 2024 Jan; 202(1):87-98. PubMed ID: 37079265
[TBL] [Abstract][Full Text] [Related]
16. The relationship between metabolic dysfunction-associated fatty liver disease and low muscle mass in an asymptomatic Korean population.
Seo JY; Cho EJ; Kim MJ; Kwak MS; Yang JI; Chung SJ; Yim JY; Yoon JW; Chung GE
J Cachexia Sarcopenia Muscle; 2022 Dec; 13(6):2953-2960. PubMed ID: 36222309
[TBL] [Abstract][Full Text] [Related]
17. Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Left Ventricular Diastolic Function and Cardiac Morphology.
Peng D; Yu Z; Wang M; Shi J; Sun L; Zhang Y; Zhao W; Chen C; Tang J; Wang C; Ni J; Wen W; Jiang J
Front Endocrinol (Lausanne); 2022; 13():935390. PubMed ID: 35928895
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of controlled attenuation parameter for assessing liver steatosis in individuals with morbid obesity before bariatric surgery.
Tavaglione F; De Vincentis A; Bruni V; Gallo IF; Carotti S; Tuccinardi D; Spagnolo G; Ciociola E; Mancina RM; Jamialahmadi O; D'Alessio R; Bottazzi B; Manfrini S; Picardi A; Perrone G; Pozzilli P; Caricato M; Vespasiani-Gentilucci U; Romeo S
Liver Int; 2022 Feb; 42(2):374-383. PubMed ID: 34890093
[TBL] [Abstract][Full Text] [Related]
19. Metabolic Dysfunction-Associated Fatty Liver Disease in Newly Diagnosed, Treatment-Naive Hypertensive Patients and Its Association with Cardiorenal Risk Markers.
Theofilis P; Vordoni A; Tsimihodimos V; Kalaitzidis RG
High Blood Press Cardiovasc Prev; 2023 Jan; 30(1):63-72. PubMed ID: 36626077
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population.
Ciardullo S; Perseghin G
Liver Int; 2021 Jun; 41(6):1290-1293. PubMed ID: 33590934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
